Sei Investments Co. bought a new stake in Affimed (NASDAQ:AFMD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 104,885 shares of the biopharmaceutical company’s stock, valued at approximately $892,000. Sei Investments Co. owned 0.11% of Affimed at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AFMD. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Affimed in the 1st quarter valued at $76,000. The Manufacturers Life Insurance Company increased its position in shares of Affimed by 23.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 62,496 shares of the biopharmaceutical company’s stock valued at $494,000 after acquiring an additional 11,852 shares during the period. Alliancebernstein L.P. increased its position in shares of Affimed by 79.7% in the 1st quarter. Alliancebernstein L.P. now owns 126,900 shares of the biopharmaceutical company’s stock valued at $1,004,000 after acquiring an additional 56,300 shares during the period. Sigma Planning Corp acquired a new position in shares of Affimed in the 1st quarter valued at $86,000. Finally, Rhumbline Advisers increased its position in shares of Affimed by 26.1% in the 1st quarter. Rhumbline Advisers now owns 101,298 shares of the biopharmaceutical company’s stock valued at $801,000 after acquiring an additional 20,944 shares during the period. 72.98% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:AFMD opened at $6.39 on Wednesday. Affimed has a one year low of $3.09 and a one year high of $11.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.37 and a current ratio of 3.38. The firm has a market cap of $628.05 million, a price-to-earnings ratio of -13.89 and a beta of 2.67. The firm’s fifty day moving average is $6.54 and its two-hundred day moving average is $7.88.
Separately, Zacks Investment Research downgraded Affimed from a “hold” rating to a “strong sell” rating in a research report on Monday, September 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $13.40.
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.
Further Reading: Strike Price
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.